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Abstract
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines
and provide feedback on the success of HIV-1 treatment and prevention programs. To accurately compare transmitted drug
resistance rates across geographic regions and times, the World Health Organization has recommended the adoption of a
consensus genotypic definition of transmitted HIV-1 drug resistance. In January 2007, we outlined criteria for developing a
list of mutations for drug-resistance surveillance and compiled a list of 80 RT and protease mutations meeting these criteria
(surveillance drug resistance mutations; SDRMs). Since January 2007, several new drugs have been approved and several
new drug-resistance mutations have been identified. In this paper, we follow the same procedures described previously to
develop an updated list of SDRMs that are likely to be useful for ongoing and future studies of transmitted drug resistance.
The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance
mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions.
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Introduction
The worldwide effort to improve treatment outcomes and
reduce transmission of HIV through optimal delivery of ART and
HIV prevention programmes must be coordinated with and
enlightened by ongoing national, regional, and global evaluations
of HIV drug resistance. One essential element in the global
evaluation is population-based surveillance of transmitted HIV
drug resistance in recently infected individuals. As HIV drug
resistance surveillance programs are underway in many countries
and regions, it has become essential to develop a standard list of
mutations to characterize the epidemiology of transmitted drug
resistance [1,2,3,4,5]. Only with a standard list of mutations is it
possible to compare the prevalence of transmitted resistance from
different times and regions and facilitate meta-analyses of
surveillance data collected by different groups at different times.
Compiling such a standard list, however, is not simple because of
the rapidly changing field of ARV therapy and the large numbers
of mutations associated with ARV drug resistance [6,7].
In 2007, we outlined four criteria for identifying surveillance
drug-resistance mutations (SDRMs) and used these criteria to
create a provisional list of SDRMs [6]. The first criterion was that
SDRMs should be recognized as causing or contributing to drug
resistance – defined as being present on three or more of five
expert lists of drug resistance mutations. The second criterion was
that mutations should be non-polymorphic and should not occur
at highly polymorphic positions. The third criterion was that the
mutation list had to be applicable to the eight most common HIV-
1 subtypes. The fourth criterion was that the list should be
parsimonious, excluding mutations resulting exceedingly rarely
from drug pressure.
Since the 2007 list was published, new drug-resistance
mutations have been identified including mutations arising from
the increased use of non-thymidine-analog containing regimens,
the expanded use of two new protease inhibitors (PIs), and the
recent approval of a new non-nucleoside RT inhibitor (NNRTI).
The number of sequences from ARV-naı¨ve persons infected with
subtype B and non-B HIV-1 viruses in our analysis dataset has
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approximately doubled since the 2007 publication, increasing the
confidence with which nonpolymorphic mutations can be
identified. In this paper, we followed the same steps used to
create the 2007 mutation list.
Methods
Identification of mutations causing or contributing to
drug resistance
Mutations that were present on three or more of the following
five expert lists – ANRS drug resistance interpretation algorithm
(2008.07), HIVdb drug resistance interpretation algorithm (4.3.7),
IAS-USA Mutations Associated With Drug Resistance (March/
April 2008), Los Alamos National Laboratories HIV Sequence
database (2007), or Rega Institute Drug Resistance Interpretation
Algorithm (7.1.1) – were considered to be recognized as causing or
contributing to drug resistance. The complete list of mutations
associated with each of these lists can be found on the Surveillance
Drug Resistance Mutation (SDRM) worksheet (http://hivdb.
stanford.edu/cgi-bin/AgMutPrev.cgi).
Identification of nonpolymorphic mutations and
mutations not occurring at highly polymorphic positions
Some drug resistance mutations occur commonly in the absence
of drug selective pressure, these polymorphic drug-resistance
mutations should not be used for surveillance of transmitted drug
resistance because they could lead to falsely elevated estimates of
transmitted resistance. For the purposes of generating a non-
polymorphic list of drug resistance mutations, we defined
nonpolymorphic mutations to be mutations present at a frequency
#0.5% in ARV-naı¨ve individuals infected with subtypes for which
.1,000 sequences were available in our dataset and at levels
.0.5% in no more than one subtype for which fewer than 1,000
sequences were available. Nonpolymorphic mutations occurring at
polymorphic positions, defined as positions with mutations
occurring at .1% in any subtype, were generally excluded.
Exceptions were made for major mutations that directly contribute
to causing resistance.
Assignment of HIV-1 subtype
A set of 100 reference sequences was compiled by combining 65
representative group M sequences curated by the Los Alamos
Sequence Database and an additional 35 samples added so that
the dataset would include three or more divergent reference
sequences for each pure subtype and many of the most common
CRFs. Neighbor joining trees were created from an alignment of
each sequence with the 100 reference sequences. Sequences
clustering within clades formed by subtypes A, B, C, D, F, G, H, J,
and K, and CRF01_AE and CRF02_AG sequences were assigned
to that clade. Sequences grouping within clades CRF_03 to
CRF_19 were assigned to that clade unless the region spanned by
the CRF mapped onto one of the pure subtypes or CRF01_AE or
CRF02_AG, in which case the sequence was assigned to one of
these. Sequences that were not within a clade were assigned to the
subtype or CRF of the closest node. For 85.4% of ARV-naive
sequences, the subtype matched the STAR program subtype [8]
subtype; for 4.5% of sequences, the subtype differed from the
STAR subtype, and for 10.1% of isolates, the STAR program did
not provide a definitive result. For the purposes of this study, we
analyzed mutation prevalence rates only within subtypes A, B, C,
D, F, G, CRF01_AE, and CRF02_AG. CRF sequences and non-
CRF recombinants that clustered with one of these eight subtypes
within protease and/or RT were also included.
Exclusion of rare mutations
The fourth consideration in creating the SDRM list was that it
should be as parsimonious as possible without sacrificing
sensitivity. To accomplish this, we excluded exceedingly rare
drug-resistance mutations defined as those mutations present at a
frequency below 0.5% among treated individuals in the subtype
having the highest prevalence of that mutation. Because the
number of isolates from treated persons for some subtypes was
low, we also required that the mutations be present in sequences
from at least two different persons with the subtype having the
highest prevalence of that mutation.
Analysis and review
We identified mutations present on three or more of the selected
lists and analyzed publicly available RT and PI sequences reported
as being from drug-naive individuals, within subtypes A, B, C, D,
F, G, CRF01_AE, and CRF02_AG, for the frequency of each
mutation by subtype. To reduce the influence of transmitted
resistance on the identification of non-polymorphic mutations
among the sequences in our dataset we excluded treatment-naı¨ve
individuals from studies of primarily infected persons in regions
with high rates of transmitted resistance and excluded sequences
with two or more mutations from the 2007 SDRM list based on
the premise that such sequences were likely to have resulted from
previous selective drug pressure. The next phase of the analysis
included only mutations that met the criteria for non-polymor-
phism.
For each of the mutations that met our criteria for non-
polymorphism and for non-occurrence at a highly polymorphic
position in the previous analysis, we examined publicly available
sequences for the frequency of each mutation among individuals
reported to be treated with the relevant drug class. This analysis
was also performed separately for each subtype. The mutations
that met the criterion for rarity were excluded from the list.
We reached the final list through review of the results of the
analysis by a panel comprising the authors of this paper. Some
mutations that occurred as low-level polymorphisms among
several subtypes were further excluded for parsimony. These are
described in the results section.
Finally, because the mutations on the resulting 2009 SDRM list
included those occurring in sequences of untreated individuals at a
frequency of 0.1% to 0.5% (and for three mutations at a frequency
of .0.5%) in one or more subtypes, we examined the frequencies
of sequences with one or more mutations on the 2009 SDRM list
for each ARV drug class and each subtype among the sequences in
the dataset from untreated persons.
Results
Identification of drug-resistance mutations
The SDRM worksheet on the HIV Drug Resistance Database
(http://hivdb.stanford.edu/cgi-bin/AgMutPrev.cgi) shows all of
the mutations present on the ANRS, HIVdb, IAS-USA, Los
Alamos, and Rega algorithm lists. Overall, 75 mutations were on
five lists including 17 NRTI, 18 NNRTI, and 40 PI-associated
mutations; 43 mutations were on four lists including 11 NRTI, 8
NNRTI, and 24 PI-associated mutations; and 42 mutations
appeared on three lists including 17 NRTI, 11 NNRTI, and 14 PI-
associated mutations.
Sequences from untreated Individuals
RT sequences from 11,586 RT inhibitor-naı¨ve individuals and
protease sequences from 15,220 PI-naı¨ve individuals were publicly
available and met the criteria to be included the analysis dataset
HIV Surveillance Mutations
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(Table 1). More than 50% of both the RT and protease sequences
were from non-subtype B viruses. The dataset contains more than
double the number of protease and RT sequences available from
untreated persons infected with viruses from both subtype B and
non-B subtypes compared with the number of sequences used to
generate the 2007 SDRM list [6]. RT and protease sequences
from more than 1,000 individuals were available for subtype A,
subtype B, subtype C, and CRF02_AG. For 70.1% of the
sequences, both the protease and RT gene were sequenced; for
17.9%, only the RT gene was sequenced; and for 12.0%, only the
protease gene was sequenced.
Sequences from treated individuals
RT sequences from 14,622 RT inhibitor-treated individuals and
protease sequences from 7,819 PI-treated individuals were publicly
available and met the criteria to be included the analysis dataset.
The relative proportions of non-B sequences compared with
subtype B sequences were considerably lower among treated
individuals than among untreated individuals. The number of RT
inhibitor-treated individuals with non-B subtypes was 3,680,
approximately 1/3 the number of individuals (10,942) with
subtype B sequences. The number of sequences from RT
inhibitor-treated persons with non-B viruses ranged from 248 for
subtype D to 1,063 for subtype C. The number of PI-treated
individuals with non-B sequences was 1,168, approximately 1/5
the number of treated individuals (6,651) with subtype B
sequences. The number of isolates from PI-treated individuals
with non-B viruses ranged from 61 for CRF01_AE to 307 for
subtype F. Non-B sequences made up 25% of the analyzable RT
sequences and 15% of the analyzable PI sequences.
NRTI-Associated SDRMs
There were 39 nonpolymorphic NRTI-associated drug resis-
tance mutations present on three or more expert lists (http://
hivdb.stanford.edu/cgi-bin/AgMutPrev.cgi). Sixteen mutations
were on five lists; nine mutations were on four lists; and 14
mutations were on three lists. Among these mutations, two
occurred at a frequency of .0.5% in subtype D infected
individuals: M41L in four (1.2%) and M184V in two (0.6%) of
324 individuals. Examination of the sequences with these
mutations displayed no evidence for sequence artifact or
epidemiological clustering.
Six nonpolymorphic NRTI-resistance mutations including
E44A, D67E, T69N, K70E, L74I, and K219N were not present
on the 2007 SDRM list. We added four of these mutations –
D67E, K70E, L74I, and K219N – to the updated SDRM list
(Table 2). Two mutations (E44A and T69N) were not added
because they occur at polymorphic positions. Moreover, T69N
occurred in 0.4%, 0.4%, and 0.5% of subtypes B, F, and
CRF01_AE, respectively.
Although they occur at polymorphic positions, we included in
the list the NRTI mutations T69D, the T69 insertions, and
V75T/M/A/S, because of their substantial contribution to
resistance to commonly-used NRTIs.
Several known NRTI-resistance mutations were excluded from
consideration as an SDRM: (i) K65N is a recently described rare
NRTI-resistance mutation, which was present on two expert lists
and which appears to have a phenotypic effect similar to K65R
[9,10]. However, it has been reported in only six NRTI-
experienced and nine NRTI-naı¨ve individuals, amd its prevalence
was less than 0.1% among sequences from treated individuals in
any subtype. (ii) A62V is an accessory NRTI-resistance mutation
which is nonpolymorphic except for its presence in 16% of subtype
A viruses due to a founder effect within the intravenous drug user
epidemic in Eastern Europe [11]; (iii) E44D and V118I were not
included because they are polymorphic in multiple subtypes; (iv)
Deletions at codon 67 were deleted from the 2007 list because
their highest frequency among treated individuals of any subtype
was 0.1%; and (v) K70G is a mutation which has an effect similar
to K70E but was present on only two expert lists and was present
at no more than 0.3% of treated individuals with any subtype.
Table 2 shows the updated list of 34 NRTI SDRMs at 15 RT
positions. The proportion of reportedly drug-naive individuals in
the dataset having one or more NRTI-associated SDRMs for each
of the eight subtypes is as follows: 0.2% in subtype G, 0.4% in
subtype F, 0.6% in subtype C, 1.3% in CRF02_AG, 1.4% in
subtype A, 2.3% in subtype B, 2.4% in subtype D, and 2.9% in
CRF01_AE.
NNRTI SDRMs
There were 31 non-polymorphic NNRTI-associated drug
resistance mutations present on three or more expert lists
(http://hivdb.stanford.edu/cgi-bin/AgMutPrev.cgi). Seventeen
mutations were on five lists; seven mutations were on four lists;
and seven mutations were on three lists. None of these mutations
occurred at a frequency of .0.5% in any subtype.
Thirteen non-polymorphic NNRTI-resistance mutations in-
cluding K101P, V179F, Y181V, and A98G (five expert lists);
G190C/T/V and K103T (four expert lists); and K103H, E138K,
F227C, K238T, and L318F (three expert lists) were not on the
2007 SDRM list. Five of these mutations, K101P, E138K, V179F,
Y181V, and F227C have been associated with reduced suscepti-
bility to the most recently approved NNRTI etravirine [12,13,14].
We added 3 of the 13 new mutations to the updated SDRM list:
K101P, V179F, and Y181V. Although V179F is an uncommon
mutation that occurs at a highly polymorphic position, this
mutation was retained because of its frequent selection by
etravirine and its profound effect on etravirine susceptibility when
it occurs in combination with Y181C/I/V [15]. The mutations
K103H/T, G190C/T/V and F227C were not added because
they occurred at a frequency of ,0.5% among ARV-experienced
individuals among published sequences. A98G, E138K and
K238T, although nonpolymorphic, occur at highly polymorphic
positions and their prevalence among NNRTI-experienced
Table 1. Numbers of Reverse Transcriptase Inhibitor (RTI) and
Protease Inhibitor (PI)-Naı¨ve Persons from Whom Publicly
Available Sequences Were Available for Analysis in 2006 and
2008.
Subtype RTI-Naı¨ve Persons PI-Naı¨ve Persons
2006 2008 % D 2006 2008 % D
B 2,240 5,672 +153 3,704 7,439 +101
Non-B Subtypes
A 499 1,305 +162 686 1,528 +123
AE 635 770 +21 684 902 +32
AG 484 1,035 +114 811 1,437 +77
C 915 2,020 +121 1025 2,182 +113
D 192 320 +69 355 515 +45
F 137 265 +93 180 598 +232
G 145 403 +178 270 619 +129
Non-B Total 3,007 6,118 +105 4011 7,781 +94
doi:10.1371/journal.pone.0004724.t001
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patients is also low. P236L, which was on the 2007 list, was
removed because its highest prevalence among treated persons in
any subtype was 0.4% and because it is associated with resistance
solely to delavirdine an NNRTI that is rarely used. G190Q, which
was on the 2007 list, was removed because its highest frequency
among treated individuals in any subtype was 0.1%. L318F was
not added because it is not consistently sequenced during
surveillance studies.
Although they occur at polymorphic postions, K101E/P,
K103N/S, V106A/M, and V179F are included in the list because
of their substantial contribution to resistance to commonly-used or
new NNRTIs.
Several known NNRTI-resistance mutations were excluded
from consideration as an SDRM because they are polymorphic in
one or more subtypes including (i) V90I which occurs in 0.7%,
6.9%, 1.8%, 1.0%, 1.7%, and 0.8% of CRF01_AE, CRF02_AG,
subtype B, subtype C, subtype D, and subtype G sequences,
respectively; (ii) K101Q which occurs in 0.9% and 0.6% of
CRF02_AG and subtype B sequences; (iii) V106I which occurs in
0.7%, 4.7%, 2.1%, 2.6%, 4.7%, and 1.6% of subtype A,
Table 2. Nucleoside RT Inhibitor Surveillance Drug Resistance Mutation (SDRM) List: 34 Mutations at 15 Positions
Position AA Lists New A (%) AE (%) AG (%) B (%) C (%) D (%) F (%) G (%)
No Rx
(Max %) Max Rx (%)
Number of individuals: 1,305 770 1,035 5,672 2,020 324 265 403 11,586 14,621
41 L 5 0 0.3 0.1 0.3 0 1.2 0 0 1.2 39
65 R 5 0.1 0 0 0 0.2 0 0 0 0.2 6.5
67 N 5 0 0 0 0 0 0 0 0 0 44
G 4 0 0 0.1 0.2 0.1 0 0 0 0.2 1.6
E 3 ! 0 0 0 0 0 0 0 0 0 1.7
69 D 4 0.1 0 0 0 0 0 0 0 0.1 7.1
ins 5 0 0 0 0 0 0 0 0 0 1.2
70 R 5 0 0.3 0 0.2 0 0 0 0 0.3 29
E 5 ! 0 0 0 0 0 0 0 0 0 1.6
74 V 5 0 0 0 0 0 0 0 0.2 0.2 7.5
I 4 ! 0 0 0 0 0 0 0 0 0 3.3
75 M 4 0 0.5 0 0 0 0 0 0 0.5 3.8
T 4 0 0 0 0 0 0 0 0 0 2.7
A 3 0 0 0 0 0.1 0 0 0 0.1 0.8
S 3 0 0 0 0 0 0 0 0 0 1.4
77 L 3 0 0.3 0 0.1 0 0 0 0 0.3 2.0
115 F 5 0 0 0 0 0 0 0 0 0 1.4
116 Y 3 0 0.1 0 0 0 0 0 0 0.1 3.3
151 M 5 0 0 0 0 0 0 0 0 0 5.2
184 V 5 0.2 0.1 0.2 0.2 0.1 0.6 0 0 0.6 61
I 5 0 0.3 0.1 0 0 0.3 0 0 0.3 2.8
210 W 5 0 0 0 0 0 0 0 0 0 25
215 Y 5 0.2 0 0 0 0 0 0 0 0.2 38
F 5 0.1 0 0 0 0 0 0 0 0.1 22
I 3 0.2 0.1 0 0 0 0 0 0 0.2 5.7
S 3 0 0.1 0.1 0.4 0 0 0.4 0 0.4 0.6
C 3 0 0 0 0.2 0 0 0 0 0.2 3.1
D 3 0 0 0 0.4 0 0.3 0 0 0.4 0.8
V 3 0 0 0 0 0 0 0 0 0 1.0
E 3 0 0 0 0.1 0 0 0 0 0.1 2.1
219 Q 5 0.2 0.4 0.4 0 0 0 0 0 0.4 25
E 5 0 0 0 0 0 0 0 0 0 9.4
N 4 ! 0.1 0.4 0.2 0.1 0 0 0 0 0.4 2.5
R 4 0.2 0 0.1 0.1 0.1 0 0 0 0.1 2.2
Sum of Prevalences: 1.4 2.9 1.3 2.3 0.6 2.4 0.4 0.2
Abbreviations: Pos – amino acid position; AA – amino acid difference from consensus B; Lists – Number of mutation lists with the mutation; New – mutations not
present on the 2007 SDRM list; No Rx – highest prevalence in untreated persons in any of the 8 listed subtypes; Max Rx – Prevalence of the mutation in the subtype with
the highest prevalence of the mutation provided the mutation is present in viruses from two or more individuals. Underlined bold mutations are those with a
prevalence .0.5% that are nonetheless included because the .0.5% prevalence is in only one subtype with fewer than 1000 sequences available for analysis.
doi:10.1371/journal.pone.0004724.t002
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CRF01_AE, subtype B, subtype D, subtype F, and subtype G
isolates; (iv) V108I which occurs in 1.3%, and 0.6% of
CRF02_AG and subtype B isolates; and (v) V179D which occurs
in 1.7% of CRF01_AE and 4.1% of subtype F isolates; and (vi)
V179E which occurs in 0.6% and 7.2% of CRF02_AG and
subtype G isolates.
Table 3 contains the updated list of 19 NNRTI SDRMs at 10
RT positions. The proportion of reportedly drug-naive individuals
in the dataset with one or more NNRTI-associated SDRM for
each of the eight subtypes would be as follows: 0% in subtypes F
and G, 0.4% in subtype A and CRF01_AE, 0.5% in subtype C,
0.5% in CRF02_AG, 0.6% in subtype D, and 0.8% in subtype B.
PI SDRMs
There were 51 non-polymorphic PI-associated drug resistance
mutations present on three or more expert lists (http://hivdb.
stanford.edu/cgi-bin/AgMutPrev.cgi). Thirty-one mutations were
on five lists; 12 mutations were on four lists; and eight mutations
were on three lists. M46I was present in 0.6% of the isolates from
902 CRF01_AE-infected individuals, K43T was present in 0.7%
of the isolates from 598 subtype F-infected individuals, and Q58E
was present in 0.6% of the isolates from 515 subtype D-infected
individuals.
Twenty mutations including L10F/R, K20T, L23I, K43T,
M46L, G48M, F53Y, Q58E, V71I/L, T74P, L76V, V82C/L,
N83D, I85V, L89V/T, and I93M were not on the 2007 SDRM
list. Of these 20 mutations K43T, Q58E, T74P, V82L, and N83D
have been newly recognized primarily because of their association
with tipranavir resistance [16]; whereas L76V and L89V have
been newly recognized primarily because of their association with
darunavir resistance [17]. M46L, which had been excluded from
the previous SDRM list because of its presence in 1.5% of 264
subtype G sequences, was added back to the list because its
prevalence decreased to 0.5% with the approximate tripling of the
number of PI-naı¨ve sequences belonging to this subtype.
We added nine of the 20 new mutations to the updated SDRM
list: L23I, M46L, G48M, F53Y, L76V, V82L/C, N83D, and
I85V. Ten mutations were not added because they occur at
polymorphic positions (L10F/R, K20T, K43T, V71I/L, T74P,
L89V/T, and I93M). Q58E was not added because it displayed
borderline polymorphism rates in multiple subtypes: 0.6% in
subtype D, 0.4% in subtype B, and 0.3% in subtype C. M46I was
retained despite occurring in 0.6% of 902 CRF01_AE isolates and
0.3% of subtype A and B isolates because it reduces susceptibility
to several PIs even in the absence of other SDRMs [18] and
because it did not occur at a frequency of .0.5% in more than
one subtype with .1,000 sequences available for analysis.
Examination of the CRF01_AE sequences with M46I revealed
no evidence for sequence artifact or epidemiological clustering.
Although they occur at polymorphic positions, we included the
protease mutations V82A/T/F/S/C/M/L because of their
substantial contribution to resistance to several PIs.
Table 4 contains the updated list of 40 PI SDRMs at 18
protease positions. The proportion of reportedly drug-naive
persons in the dataset having one or more PI-associated SDRMs
for each of the eight subtypes would be as follows: 0.4% in subtype
Table 3. Non-Nucleoside RT Inhibitor Surveillance Drug Resistance Mutation (SDRM) List: 19 Mutations at 10 Positions
Position AA Lists New A (%) AE (%) AG (%) B (%) C (%) D (%) F (%) G (%)
No Rx
(Max %) Max Rx (%)
Number of individuals: 1,305 770 1,035 5,672 2,020 324 265 403 11,784 14,621
100 I 5 0 0 0 0 0 0 0 0 0 5.4
101 E 5 0 0 0 0.2 0 0 0 0 0.2 6.4
P 5 ! 0 0 0 0 0 0 0 0 0 1.4
103 N 5 0.1 0 0.2 0.3 0.2 0 0 0 0.3 40
S 4 0 0 0 0 0 0 0 0 0 0.6
106 M 5 0 0 0 0 0 0 0 0 0 12
A 5 0 0 0.1 0 0 0 0 0 0.1 1.1
179 F 5 ! 0 0 0 0 0 0 0 0 0 0.2
181 C 5 0.1 0.1 0.1 0 0.1 0 0 0 0.1 14
I 5 0.1 0 0 0 0 0 0 0 0.1 1.1
V 5 ! 0 0 0 0 0 0 0 0 0 1.1
188 L 5 0 0.3 0 0 0 0 0 0 0.3 2.4
H 5 0 0 0 0.1 0 0.3 0 0 0.3 0.6
C 5 0 0 0.1 0 0 0 0 0 0.1 0.9
190 A 5 0.1 0 0 0 0.1 0.3 0 0 0.3 10
S 5 0 0 0 0 0 0 0 0 0 1.6
E 4 0 0 0.1 0 0 0 0 0 0.1 0.5
225 H 5 0 0 0 0 0 0 0 0 0 7.6
230 L 3 0 0 0 0 0 0 0 0 0 3.6
Sum of Prevalences: 0.4 0.4 0.6 0.7 0.5 0.6 0 0
Abbreviations: Pos – amino acid position; AA – amino acid difference from consensus B; Lists – Number of mutation lists with the mutation; New – mutations not
present on the 2007 SDRM list; No Rx – highest prevalence in untreated persons in any of the 8 listed subtypes; Max Rx – Prevalence of the mutation in the subtype with
the highest prevalence of the mutation provided the mutation is present in viruses from two or more individuals.
doi:10.1371/journal.pone.0004724.t003
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Table 4. Protease Inhibitor (PI) Surveillance Drug Resistance Mutation (SDRM) List: 40 Mutations at 18 Positions*
Position AA New Lists A (%) AE (%) AG (%) B (%) C (%) D (%) F (%) G (%) No Rx (%) Max Rx (%)
Number of individuals: 1,528 902 1,437 7,439 2,182 515 598 619 15,220 7,886
23 I ! 3 0.1 0.1 0 0 0 0 0 0 0.1 2.1
24 I 5 0 0 0.1 0 0 0 0.2 0 0.2 11
30 N 5 0 0 0 0 0 0 0 0 0 9.0
32 I 5 0 0 0.1 0 0 0 0 0 0.1 7.3
46 I 5 0.3 0.6 0.1 0.4 0.2 0 0.2 0 0.6 29
L ! 5 0.3 0.2 0.3 0.3 0.1 0.2 0.2 0.5 0.5 13
47 V 5 0 0 0 0 0.1 0.2 0 0.3 0.3 6.8
A 5 0 0 0 0 0 0 0 0 0 0.5
48 V 5 0 0 0 0 0 0 0 0 0 5.7
M ! 3 0 0 0 0 0 0 0 0 0 2.3
50 V 5 0 0 0 0 0 0 0 0 0 2.5
L 5 0 0 0 0 0 0 0 0 0 1.8
53 L 5 0 0.1 0 0 0 0 0 0.2 0.2 7.8
Y ! 4 0.1 0 0.1 0 0 0 0 0 0.1 0.6
54 V 5 0 0 0 0 0 0 0 0 0 43
L 5 0 0 0 0 0 0 0 0 0 4.6
M 5 0 0 0 0 0 0 0 0 0 4.3
A 5 0 0 0 0 0 0 0 0 0 2.6
T 5 0.1 0 0 0 0 0 0 0 0.1 1.7
S 5 0 0 0 0 0 0 0 0 0 1.7
73 S 5 0 0 0.1 0 0 0 0 0 0.1 13
T 4 0 0 0 0 0 0 0 0 0 4.3
C 3 0 0 0 0 0 0 0 0 0 2.0
A 4 0 0 0 0 0 0 0 0 0 0.8
76 V ! 5 0 0 0 0 0.1 0 0 0 0.1 4.3
82 A 5 0 0 0 0 0.1 0 0.2 0 0.2 30
T 5 0 0 0 0 0 0 0 0 0 13
F 5 0 0 0 0 0 0 0 0 0 2.1
S 5 0 0 0 0 0 0 0 0 0 1.6
C ! 3 0 0 0 0 0 0 0 0 0 0.8
M 4 0 0 0 0 0 0 0 0 0 2.5
L ! 4 0 0 0 0 0 0 0 0 0 0.5
83 D ! 3 0 0 0.1 0 0.1 0 0 0 0.1 9.3
84 V 5 0 0.1 0 0 0 0 0 0 0.1 21
A 4 0 0 0 0 0 0 0 0 0 0.8
C 3 0 0 0 0 0 0 0 0 0 0.8
85 V ! 4 0.1 0 0.1 0.1 0.2 0 0.2 0 0.2 6.4
88 D 5 0 0.1 0.1 0.1 0 0 0 0.2 0.2 6.4
S 5 0 0 0 0 0 0 0 0 0 3.4
90 M 5 0.1 0.3 0 0.1 0.1 0 0 0.5 0.5 45
Sum of Prevalences: 1.1 1.5 1.1 1.0 1.0 0.4 1.2 1.2
Abbreviations: Pos – amino acid position; AA – amino acid difference from consensus B; Lists – Number of mutation lists with the mutation; New – mutations not
present on the 2007 SDRM list; No Rx – highest prevalence in untreated persons in any of the 8 listed subtypes; Max Rx – Prevalence of the mutation in the subtype with
the highest prevalence of the mutation provided the mutation is present in viruses from two or more individuals. Underlined bold mutations are those with a
prevalence .0.5% that are nonetheless included because the .0.5% prevalence occurs in only one subtype with fewer than 1000 sequences or in fewer than 1000
sequences available for analysis.
doi:10.1371/journal.pone.0004724.t004
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D, 1.0% in subtypes B and C, 1.1% in subtype A and CRF01_AG,
1.2% in subtypes F and G, and 1.5% in CRF01_AE.
Discussion
The value of a standard SDRM list lies not just in obtaining an
accurate estimation of transmitted resistance but also in making it
possible to compare estimates of transmitted resistance from
different regions and times. The SDRM list proposed in 2007
proved useful in a number of recently published surveys of
transmitted ARV resistance in populations in which ARVs were
recently introduced. These studies, performed in sub-Saharan
Africa [19,20,21,22,23,24] and South and South-East Asia
[25,26], reported very low levels of SDRMs consistent with the
very recent introduction of ARVs into these regions.
The updated 2009 SDRM list developed in this analysis has 93
mutations including 34 NRTI-associated resistance mutations at
15 RT positions, 19 NNRTI-associated resistance mutations at 10
RT positions, and 40 PI-associated resistance mutations at 18
protease positions. The 2009 list contains 77 of the 80 mutations
on the 2007 list and 16 additional mutations including four new
NRTI-associated resistance mutations (D67E, K70E, L74I, and
K219N), three new NNRTI-associated resistance mutations
(K101P, V179F, and Y181V), and nine new PI-associated resistant
mutations (L23I, M46L, G48M, F53Y, L76V, V82C/L, N83D,
and I85V). Of these 16 new mutations, nine owe their recognition
to specific trends in ARV development and usage: the increased
use of non-thymidine containing NRTI regimens (K70E and
L74I), the increased recognition of mutations associated with
etravirine (K101P, V179F and Y181V), tipranavir (V82L and
N83D), and darunavir (L76V) resistance. The remaining 7
mutations, owe their inclusion to the expansion in the number
of mutations in the five expert system lists.
The challenge in creating an SDRM list is in choosing
mutations that are both highly sensitive and specific indicators of
transmitted drug resistance. Attaining a high sensitivity for
transmitted resistance is challenging because the large number of
HIV-1 drug-resistance mutations has the potential to make the list
unwieldy. Therefore, to limit the number of SDRMs without
sacrificing sensitivity, we included only established drug-resistance
mutations, which with one exception (the etravirine-associated
mutation V179F) occurred at a prevalence of at least 0.5% in one
or more subtypes from ARV-experienced individuals.
Attaining a high specificity for transmitted resistance is
challenging because many drug-resistance mutations occur
naturally in untreated individuals. Although we selected only
nonpolymorphic drug-resistance mutations – defined as those
occurring at a prevalence #0.5% in untreated individuals in
subtypes for which .1,000 sequences were available and at levels
.0.5% in no more than one subtype for which fewer than 1,000
sequences were available – it is likely that specificity may still be
compromised because ‘‘nonpolymorphic’’ mutations occasionally
occur in the absence of selective drug pressure.
Indeed, among the 93 mutations on the 2009 SDRM list, three
occurred at a frequency .0.5% (in a subtype with fewer than
1,000 sequences) and 46 occurred at a frequency between 0.1%
and 0.5% in at least one subtype. The median prevalence of
having one or more SDRMs in the eight subtypes in our dataset
was 1.3% for the NRTIs, 0.5% for the NNRTIs, and 1.1% for the
PIs. It is not possible to report an overall prevalence of sequences
in our dataset having one or more mutations on the list for all
three drug classes because the denominators and the individuals
providing sequences for the RT and protease classes were
different. However, the overall false-positive ‘‘prevalence of
resistance’’ (based on the presence of low-level polymorphisms
rather than true transmitted resistance) using our list in studies of
reportedly drug-naive individuals infected with subtypes
CRF02_AG, D, B, or CRF01_AE would be likely to be .3%
based on the individual drug class prevalences. The use of other
lists to determine transmitted resistance would result in even
higher false-positive rates of transmitted resistance, because most
include additional polymorphic mutations which occur at .0.5%
in the absence of drug pressure.
A stricter list, which included only mutations occurring in 0% of
ARV-naı¨ve individuals in all subtypes for each drug class would
eliminate this background level of drug resistance in untreated
persons. However, it would be impractical, because it would
eliminate many important drug resistance mutations in strains
likely to be transmitted from treated individuals.
We hypothesize that the non-zero background level of
mutations at many drug-resistance positions has two explanations.
First several SDRMs may be genuinely polymorphic occurring at
low proportions in the absence of selective drug pressure (albeit
below our defined threshold of 0.5%). This low-level polymor-
phism may be a result of HIV-1’s high error rate in combination
with cytotoxic T lymphocyte (CTL) immune selection pressure.
For example, the three mutations present at a frequency of.0.5%
in untreated individuals – the protease mutation M46I (0.6% of
CRF01_AE sequences from 902 ARV-naı¨ve individuals) and the
RT mutations M41L and M184V (1.2% and 0.6%, respectively, of
subtype D sequences from 324 ARV-naı¨ve individuals) – are each
situated at terminal anchoring positions of known CTL epitopes
[27] and the protease mutation M46I has been reported to disrupt
recognition of the HLA-A2-restricted epitope KMIGGIGGFI
encompassing protease positions 45 to 54 [28].
Second, it may be that sequences from some individuals with
unreported prior treatment, or in whom resistance was transmit-
ted, were present in our ARV-naı¨ve dataset. Indeed, prior to the
surveillance programs established by the WHO, most sequences
obtained from reportedly ARV-naive individuals were from parts
of the world in which ARVs had been in widespread use or were
from tertiary care centers in low-income countries. In both types of
study, the risk of unreported prior treatment is likely to be higher
than in studies with exclusion criteria designed to limit the
likelihood of including individuals with unreported previous
treatment.
Experts who propose that a threshold of 2–3% be used to
signal a need for undertaking resource-intensive measures to
investigate or control transmission of drug-resistant HIV should
consider their proposals in light of our results. Regardless of the
list that is used to define mutations associated with transmitted
resistance, the occurrence of polymorphic resistance-related
mutations at low levels among some sequences studied is highly
probable. The potential inclusion of some previously treated
individuals, no matter how strict the criteria, is also possible. The
confluence of minimally polymorphic drug resistance mutations
and unrecognized ARV exposure may lead to falsely elevated
estimates of transmitted resistance. Studies of transmitted drug
resistance must be designed and interpreted with caution.
Specifically, it is essential to minimize the risk that previously
treated individuals are included in surveillance studies. Second,
transmitted resistance should be estimated separately for specific
drug classes rather than reporting an overall prevalence of
‘‘transmitted resistance’’, which will multiply the effect of low-
level polymorphisms. Also, the occurrence of mutations associ-
ated with a drug or drug class seldom or never used in a country
or region should not be considered as strong evidence for
resistance transmission.
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Importantly, the SDRM list provided in this paper is not
designed to be used for individual patient management; in such
cases we recommend the use of other clinical based algorithms. In
conclusion, the extensive mutation frequency data summarized in
this paper provides a useful context in which mutation prevalence
data from population-based surveillance studies of transmitted
resistance can be interpreted.
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